Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Excellair
- Development stage
- Unknown
- Lead developer
- ZaBeCor Pharmaceutical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Administration
- Inhalation, Intranasal
01
Overview
Excellair is an investigational small interfering RNA (siRNA) therapeutic developed by ZaBeCor Pharmaceuticals. It targets the signaling protein Syk kinase, a key mediator in the inflammatory cascade. By inhibiting Syk kinase, Excellair aims to block an initial step in inflammation, thereby preventing the release of multiple inflammatory mediators involved in diseases such as asthma and other inflammatory conditions. Unlike treatments that inhibit only one mediator (e.g., leukotriene or TNF inhibitors), targeting Syk kinase may provide broader anti-inflammatory effects. The drug has been studied for asthma and is being considered for other inflammatory diseases including allergic rhinitis, rheumatoid arthritis, cardiovascular disease, and additional disorders[3].
- Brand names
- Excellair
- Other names
- Excellair
02
Targets
SYK (Spleen Tyrosine Kinase)
Beyond the preview
Go deeper on Excellair.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Excellair.